Better Therapeutics, Inc. (BTTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Francisco, CA, United States. The current CEO is David Perry.
BTTX has IPO date of 2021-03-17, 54 full-time employees, listed on the Other OTC, a market capitalization of $5.45K.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
